Bohdiewicz P J
Nuclear Medicine Department, William Beaumont Hospital, Royal Oak, MI 48073-6769, USA.
J Nucl Med Technol. 1998 Sep;26(3):155-63; quiz 170-1.
Colon cancer is the second most common cause of cancer mortality. Ovarian cancer is the most common gynecologic malignancy cause of death in women. A labeled monoclonal antibody attaches to a tumor-associated antigen and allows these tumor masses to be imaged or treated, depending on the radionuclide used. Indium-111 satumomab pendetide was the first labeled monoclonal antibody to be approved by the Food and Drug Administration (FDA) for tumor imaging. It is reactive with most colorectal and ovarian cancers, as well as other cancers. After reading this article, the technologist will understand the FDA approval process, phase trial results, safety and adverse reactions, human antimurine antibody response, indications, imaging protocol, and strengths and weaknesses of imaging with satumomab pendetide. Representative cases are presented.
结肠癌是癌症死亡的第二大常见原因。卵巢癌是女性妇科恶性肿瘤致死的最常见原因。标记单克隆抗体附着于肿瘤相关抗原，根据所使用的放射性核素，可对这些肿瘤块进行成像或治疗。铟-111 奥曲肽是首个获得美国食品药品监督管理局（FDA）批准用于肿瘤成像的标记单克隆抗体。它对大多数结直肠癌、卵巢癌以及其他癌症具有反应性。阅读本文后，技术人员将了解 FDA 的批准过程、各阶段试验结果、安全性和不良反应、人抗鼠抗体反应、适应症、成像方案以及奥曲肽成像的优缺点。文中还展示了代表性病例。
